New England Journal of Medicine May 26, 2022

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Patrick M. Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, et al.

Bottom Line

In patients with resectable early-stage non-small-cell lung cancer, neoadjuvant treatment with nivolumab plus platinum-based chemotherapy significantly prolonged event-free survival and increased pathological complete response rates compared to chemotherapy alone, without compromising surgical feasibility.

Key Findings

1. Median event-free survival (EFS) was significantly longer with nivolumab plus chemotherapy at 31.6 months compared to 20.8 months with chemotherapy alone (HR 0.63; 97.38% CI, 0.43 to 0.91; P=0.005).

2. The pathological complete response (pCR) rate was significantly higher in the nivolumab group (24.0%) versus the control group (2.2%) (Odds Ratio 13.94; 99% CI, 3.49 to 55.75; P<0.001).

3. Estimated 2-year EFS rates were 63.8% for the nivolumab plus chemotherapy arm compared to 45.8% for the chemotherapy alone arm.

4. The addition of nivolumab did not impede surgical feasibility, with 83.2% of patients in the combination group undergoing definitive surgery compared to 75.4% in the chemotherapy alone group.

5. Grade 3 or 4 treatment-related adverse events occurred at similar rates in both arms: 33.5% in the nivolumab group and 36.9% in the chemotherapy group.

Study Design

Design

Phase 3 RCT

Open-Label

Sample

358

Patients

Duration

21.0 mo (minimum)

Median

Setting

Multicenter, global

Population Adults with previously untreated, resectable stage IB (≥4 cm) to IIIA non-small-cell lung cancer (NSCLC), an ECOG performance status of 0 or 1, and no known sensitizing EGFR mutations or ALK translocations.

Intervention Nivolumab 360 mg plus platinum-doublet chemotherapy every 3 weeks for 3 cycles, followed by surgical resection.

Comparator Platinum-doublet chemotherapy alone every 3 weeks for 3 cycles, followed by surgical resection.

Outcome Event-free survival (EFS) and pathological complete response (pCR), both evaluated by blinded independent review.

Study Limitations

• The open-label design could introduce bias in treatment delivery and surgical decisions, though the primary endpoints were assessed by blinded independent central review.

• Overall survival data were immature at the time of the primary analysis.

• Patients with known EGFR mutations or ALK translocations were excluded, limiting the generalizability of these findings to those specific oncogene-driven subgroups.

• The study design evaluated a neoadjuvant-only immunotherapy approach and did not assess the independent or additive contribution of postoperative adjuvant immunotherapy.

Clinical Significance

CheckMate 816 established neoadjuvant nivolumab plus platinum-doublet chemotherapy as a new standard of care for eligible patients with resectable NSCLC, marking the first FDA approval for neoadjuvant chemoimmunotherapy in early-stage lung cancer and representing a major paradigm shift aimed at improving curative outcomes.

Historical Context

Historically, early-stage resectable NSCLC has had high rates of disease recurrence and death even after definitive surgery. Adjuvant and neoadjuvant chemotherapy provided only a modest absolute survival benefit of approximately 5% at 5 years. Following the tremendous success of immune checkpoint inhibitors (such as the PD-1 inhibitor nivolumab) in metastatic NSCLC, trials were initiated to move these agents into earlier disease settings. CheckMate 816 was a landmark phase 3 trial that demonstrated the definitive superiority of neoadjuvant chemoimmunotherapy over chemotherapy alone, leading to a paradigm shift in thoracic oncology.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the mechanism of action of nivolumab, and why does combining it with chemotherapy theoretically improve outcomes in the neoadjuvant setting compared to giving it post-operatively (adjuvantly)?

Key Response

This tests foundational knowledge of PD-1 inhibition and the immunological concept that neoadjuvant immunotherapy relies on the presence of the bulk tumor, intact lymphatics, and a diverse array of neoantigens to prime a more robust, systemic anti-tumor T-cell response before the tumor is surgically removed.

Resident

A 60-year-old patient with stage IIIA NSCLC is considering neoadjuvant nivolumab plus chemotherapy. What are the key immune-related adverse events you must monitor for during this preoperative period, and how might a severe toxicity impact their definitive surgical management?

Key Response

Focuses on practical clinical monitoring for irAEs (like pneumonitis, thyroiditis, or hepatitis) and highlights the real-world consequence that significant neoadjuvant toxicity could cause delays, increased surgical complications, or even the cancellation of curative-intent surgery.

Fellow

CheckMate-816 demonstrated a significant improvement in pathological complete response (pCR) and event-free survival (EFS). How reliably does pCR act as a surrogate for long-term overall survival in early-stage NSCLC treated with immunotherapy, and how should a finding of residual viable tumor at the time of surgery influence your adjuvant treatment strategy?

Key Response

Addresses the nuanced debate regarding surrogate endpoints in oncology and explores a major current clinical dilemma: the lack of definitive prospective data on how to tailor adjuvant systemic therapy if a patient fails to achieve a pCR after neoadjuvant chemo-immunotherapy.

Attending

Given the success of CheckMate-816 alongside adjuvant immunotherapy trials like IMpower010 and PEARLS/KEYNOTE-091, how do you synthesize these data to decide whether a patient with resectable stage II-IIIA NSCLC should receive a neoadjuvant chemo-immunotherapy approach versus upfront surgery followed by adjuvant immunotherapy?

Key Response

Sparks high-level discussion on sequencing, patient selection, multidisciplinary team coordination, utilization of tumor biomarkers (e.g., PD-L1 status, ctDNA), and the inherent challenges of cross-trial comparisons when determining the optimal perioperative strategy for an individual patient.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The trial utilized a hierarchical testing strategy for its dual primary endpoints (pCR and EFS). From a biostatistical perspective, what are the advantages and limitations of this approach in immuno-oncology trials, and how might violation of the proportional hazards assumption impact the interpretation of the EFS hazard ratio?

Key Response

Critiques the statistical design. Hierarchical testing rigidly controls type I error but can complicate interpretation if late endpoints are immature. Furthermore, it addresses the non-proportional hazards commonly seen in immunotherapy trials (e.g., delayed separation of Kaplan-Meier curves), which can make a single hazard ratio misleading.

Journal Editor

When critically appraising the methodology of CheckMate-816, how do you evaluate the potential for assessment bias in the primary endpoint of event-free survival (EFS), considering that 'events' include surgical delays or cancellations in an open-label trial design?

Key Response

Flags a critical methodological vulnerability for peer review: in trials involving surgical endpoints, events preventing surgery can have subjective components. An open-label design means investigators know the treatment arm, which could subtly influence their decisions on whether a patient with marginal toxicity or radiographic pseudo-progression is still a surgical candidate.

Guideline Committee

Based on CheckMate-816 data, should neoadjuvant nivolumab plus chemotherapy receive a uniform Category 1 recommendation for all patients with stage IB-IIIA resectable NSCLC, or should current guidelines mandate upfront molecular testing and restrict this recommendation based on PD-L1 expression or the presence of actionable driver mutations?

Key Response

Links directly to guideline formulation. Patients with known EGFR/ALK mutations were appropriately excluded from CheckMate-816. Current NCCN guidelines emphasize biomarker testing prior to neoadjuvant therapy, as treating mutation-positive patients with neoadjuvant immunotherapy yields poor responses and significantly increases the risk of severe toxicity if they later require targeted TKI therapy.

Clinical Landscape

Noteworthy Related Trials

2023

KEYNOTE-671 Trial

n = 797 · NEJM

Tested

Neoadjuvant pembrolizumab + chemotherapy, then adjuvant pembrolizumab

Population

Resectable stage II, IIIA, or IIIB NSCLC

Comparator

Neoadjuvant placebo + chemotherapy, then adjuvant placebo

Endpoint

Event-free survival and Overall survival

Key result: Perioperative pembrolizumab significantly improved event-free survival and overall survival compared to chemotherapy alone.

2023

AEGEAN Trial

n = 802 · NEJM

Tested

Neoadjuvant durvalumab + chemotherapy, then adjuvant durvalumab

Population

Resectable stage II to IIIB NSCLC

Comparator

Neoadjuvant placebo + chemotherapy, then adjuvant placebo

Endpoint

Event-free survival and Pathological complete response

Key result: Perioperative durvalumab led to significantly longer event-free survival and a higher incidence of pathological complete response than chemotherapy alone.

2023

NADIM II Trial

n = 86 · NEJM

Tested

Neoadjuvant nivolumab + chemotherapy

Population

Resectable stage IIIA-IIIB NSCLC

Comparator

Neoadjuvant chemotherapy alone

Endpoint

Pathological complete response

Key result: Neoadjuvant nivolumab plus chemotherapy resulted in a significantly higher percentage of patients with a pathological complete response.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis